We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+13.99%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$216M
AUM Growth
+$6.9M
Cap. Flow
-$12.7M
Cap. Flow %
-5.89%
Top 10 Hldgs %
39.36%
Holding
92
New
7
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
EVO icon
Evotec
EVO
+$1.42M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.3M
3
AMGN icon
Amgen
AMGN
+$1.04M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$620K
5
GPCR icon
Structure Therapeutics
GPCR
+$544K

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$908K
2
XLE icon
State Street Energy Select Sector SPDR ETF
XLE
+$562K
3
XNCR icon
Xencor
XNCR
+$558K
4
ORCL icon
Oracle
ORCL
+$484K
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$462K

Sector Composition

Rank Sector Weight
1 Healthcare 30.72%
2 Technology 27.13%
3 Consumer Discretionary 7.96%
4 Communication Services 7.9%
5 Financials 4.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MU icon
1
Micron Technology
MU
$890B
$24.2M 11.21%
196,250
+1,250
+0.6% +$117K
GOOG icon
2
Alphabet (Google) Class C
GOOG
$4.18T
$10.1M 4.69%
57,000
– –
AMZN icon
3
Amazon
AMZN
$2.5T
$7.87M 3.65%
35,850
+2,500
+7% +$495K
ARGX icon
4
argenx
ARGX
$55.3B
$7.52M 3.49%
13,650
-700
-5% -$406K
ORCL icon
5
Oracle
ORCL
$349B
$7.32M 3.39%
33,500
-3,000
-8% -$484K
IAU icon
6
iShares Gold Trust
IAU
$63.8B
$6.24M 2.89%
100,000
– –
BAC icon
7
Bank of America
BAC
$434B
$5.65M 2.62%
119,500
– –
ET icon
8
Energy Transfer Partners
ET
$69.6B
$5.45M 2.53%
300,500
– –
GDX icon
9
VanEck Gold Miners ETF
GDX
$23.1B
$5.34M 2.47%
102,500
+12,500
+14% +$620K
MU icon
10
PUT
Micron Technology
MU
$890B
$5.24M 2.43%
+42,500
New +$3.97M
LLY icon
11
Eli Lilly
LLY
$1.09T
$5.16M 2.39%
6,625
+375
+6% +$291K
UBER icon
12
Uber
UBER
$146B
$5.13M 2.38%
55,000
+5,000
+10% +$412K
AMD icon
13
Advanced Micro Devices
AMD
$734B
$4.97M 2.3%
35,000
-3,000
-8% -$327K
REGN icon
14
Regeneron Pharmaceuticals
REGN
$72.9B
$4.93M 2.29%
9,400
+500
+6% +$279K
EVO icon
15
Evotec
EVO
$689M
$4.68M 2.17%
1,114,493
+362,914
+48% +$1.42M
GLD icon
16
SPDR Gold Trust
GLD
$133B
$4.57M 2.12%
15,000
-3,000
-17% -$908K
BIDU icon
17
Baidu
BIDU
$36.5B
$4.5M 2.09%
52,500
– –
BABA icon
18
Alibaba
BABA
$281B
$4.44M 2.06%
39,150
+350
+0.9% +$41.4K
CSCO icon
19
Cisco
CSCO
$457B
$3.99M 1.85%
57,500
-7,500
-12% -$461K
LFCR icon
20
Lifecore Biomedical
LFCR
$164M
$3.76M 1.74%
462,987
-20,013
-4% -$135K
IONS icon
21
Ionis Pharmaceuticals
IONS
$9.03B
$3.63M 1.68%
91,750
-3,250
-3% -$106K
SLV icon
22
iShares Silver Trust
SLV
$28.5B
$3.28M 1.52%
100,000
– –
AZN icon
23
AstraZeneca
AZN
$270B
$3.2M 1.48%
22,900
– –
ZLAB icon
24
Zai Lab
ZLAB
$2.09B
$3.18M 1.47%
91,000
+1,000
+1% +$32.9K
NAMS icon
25
NewAmsterdam Pharma
NAMS
$3.28B
$3.12M 1.45%
172,500
– –
1
2 3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
AWM
Able Wealth Management Toms River, New Jersey $374M AUM 12.51% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return

DCF Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, DCF Advisers held 92 positions worth $216M, up 3.3% from $209M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

DCF Advisers withdrew a net $12.7M in Q2 2025, closing 8 positions and reducing 20 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $462K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, DCF Advisers opened a new position in Structure Therapeutics worth $513K.

  • DCF Advisers's largest Q2 2025 buy was Structure Therapeutics: 24,750 shares worth $513K.
  • DCF Advisers added most to Evotec in Q2 2025, an estimated $1.42M increase.
  • DCF Advisers's biggest Q2 2025 reduction was SPDR Gold Trust, cutting an estimated $908K.
  • DCF Advisers fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $462K.
  • DCF Advisers's ten largest holdings make up 39% of its $216M portfolio in Q2 2025.
  • DCF Advisers opened 7 new positions and closed 8 in Q2 2025.
  • DCF Advisers's portfolio value rose 3.3% quarter-over-quarter to $216M.

Based on DCF Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.